FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn ...
Healthline2d
Do You Need to Treat Asymptomatic Crohn’s Disease?
Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...
Rolling Out10d
Key signs that might indicate you have Crohn’s disease
Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...
Medscape4d
FDA OKs Guselkumab for Crohn’s Disease
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Rheumatology Advisor1d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Medscape9d
Can Ileocaecal Resection Cut Corticosteroid Use in Crohn's?
In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...
Fierce Pharma8d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Healio8d
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The Canadian Press on MSN4d
AI can predict premature death among people with inflammatory bowel disease: study
A new study suggests AI can predict premature death among people who have inflammatory bowel disease, also known as Crohn's ...